Metraipolis › archive › dc_c2f3d9874337

Real-world study of adebrelimab as first-line therapy for extensive-stage small cell lung cancer: a retrospective study — Europe PMC PMID:41159026

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/41159026
DOI
10.3389/fimmu.2025.1678020
License (as archived)
solo-consultazione
Archived
2026-11-09T09:27:44.237Z
SHA-256 of the archived text
cb397214b3fb25b86a18a1569d0e906ac1cde737904e07e9d28f6b6985b27e41
Stable URL of this page
https://metraipolis.com/documento/dc_c2f3d9874337

How to cite

Real-world study of adebrelimab as first-line therapy for extensive-stage small cell lung cancer: a retrospective study — Europe PMC PMID:41159026 — Europe PMC (en), https://europepmc.org/article/MED/41159026 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_c2f3d9874337 (Metraipolis archive dc_c2f3d9874337, sha256 cb397214b3fb25b86a18a1569d0e906ac1cde737904e07e9d28f6b6985b27e41)
BibTeX
@misc{dcc2f3d9874337,
  title = {Real-world study of adebrelimab as first-line therapy for extensive-stage small cell lung cancer: a retrospective study — Europe PMC PMID:41159026},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/41159026},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_c2f3d9874337; sha256 cb397214b3fb25b86a18a1569d0e906ac1cde737904e07e9d28f6b6985b27e41},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/41159026. Agents can read the archived copy with the MCP tool read_document.